6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Items 301–400 of 793
Zhang, C., Liu, Y., Wang, Y., Ge, X., Jiao, T., Yin, J., Wang, K., Li, C., Guo, S., Xie, X., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01394 · Cited by 43
Bile Acid Metabolism in Health and Disease
Li, T., & Chiang, J. Y. L. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch23 · Cited by 42
Peng, Z., Chen, J., Drachenberg, C. B., Raufman, J., & Xie, G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004361 · Cited by 41
Tognolini, M., Incerti, M., Hassan‐Mohamed, I., Giorgio, C., Russo, S., Bruni, R., Lelli, B., Bracci, L., Noberini, R., Pasquale, E. B., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200102 · Cited by 39
Treatment of primary biliary cholangitis ursodeoxycholic acid non‐responders: A systematic review
Suraweera, D., Rahal, H., Jimenez, M., Viramontes, M., Choi, G., & Saab, S. (2017) · Liver International · doi:10.1111/liv.13477 · Cited by 38
Gomez, E., Garcia Buey, L., Molina, E., Casado, M., Conde, I., Berenguer, M., Jorquera, F., Simón, M., Olveira, A., Hernández‐Guerra, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16181 · Cited by 41
Steroidal Scaffolds as FXR and GPBAR1 Ligands: From Chemistry to Therapeutical Application
Sepe, V., Distrutti, E., Limongelli, V., Fiorucci, S., & Zampella, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.54 · Cited by 37
Self-citationCarino, A., Marchianò, S., Biagioli, M., Fiorucci, C., Zampella, A., Monti, M. C., Morretta, E., Bordoni, M., Giorgio, C. D., Roselli, R., et al. (2019) · Nutrients · doi:10.3390/nu11051132 · Cited by 38
“In 2002 we have reported the discovery of 6-ethyl-chenodeoxycholic acid [CDCA], then christened obeticholic acid (OCA), a semisynthetic derivative of CDCA [24], and shown that this agent effectively attenuates the development of liver steatosis in genetic models of NASH [25,26].”
BackgroundSelf-citationMontaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes
Wu, Y., Zhou, A., Tang, L., Lei, Y., Tang, B., & Zhang, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6138438 · Cited by 45
Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis
Kulkarni, A. V., Tevethia, H. V., Arab, J. P., Cândia, R., Premkumar, M., Kumar, P., Sharma, M., Reddy, D. N., & Padaki, N. R. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101675 · Cited by 43
Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders
Appelman, M. D., van der Veen, S. W., & van Mil, S. W. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.729828 · Cited by 41
“However, these intrinsic protective mechanisms are not sufficient to prevent cholestatic liver injury (23, 24).”
BackgroundObeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 47
“The discovery of OCA was due to two different teams of investigators at the University of Peru-gia, a chemistry team lead by Prof. Roberto Pellicciari and a gastroenterology/hepatology team lead by Prof. Stefano Fiorucci [25].”
InfluentialSelf-citationNew Therapies for Primary Biliary Cirrhosis
Floreani, A., Franceschet, I., Perini, L., Cazzagon, N., Gershwin, M. E., & Bowlus, C. L. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8456-5 · Cited by 38
Beneficial effects of bile acid receptor agonists in pulmonary disease models
Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385760 · Cited by 43
“alpha position of CDCA, exhibits an approximately 100-fold greater FXR agonistic activity [67].”
BackgroundSelf-citationObeticholic acid in primary biliary cholangitis: where we stand
Manne, V., & Kowdley, K. V. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000525 · Cited by 44
Medical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 39
Marchianò, S., Biagioli, M., Morretta, E., Giorgio, C. D., Roselli, R., Bordoni, M., Bellini, R., Urbani, G., Massa, C., Monti, M. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28647-4 · Cited by 39
Self-citationCurrent Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“Obeticholic acid (OCA), also known as INT-747, is a potent and selective FXR agonist derived from chenodeoxycholic acid (CDCA), a natural bile acid [113].”
Liu, Y., Zhu, J., Jin, Y., Sun, Z., Wu, X., Zhou, H., & Yang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-58809-z · Cited by 46
“In addition, when Fxr was activatedbytheagonistGW4064,orobeticholicacid(OCA) 41 , Bsep and Shp expression increased, which was blunted in the YAP * MHOs (Fig.”
Akwabi-Ameyaw, A., Caravella, J. A., Chen, L., Creech, K. L., Deaton, D. N., Madauss, K. P., Marr, H. B., Miller, A. B., Navas, F., Parks, D. J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.034 · Cited by 37
Self-citationAdvances in pharmacotherapy for primary biliary cirrhosis
Mousa, H. S., Lleò, A., Invernizzi, P., Bowlus, C. L., & Gershwin, M. E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.998650 · Cited by 40
“FXR activation by OCA also has important anti-inflammatory effects evident by reduced cytokine production [52].”
BackgroundInfluentialDash, A., Figler, R. A., Blackman, B. R., Marukian, S., Collado, M. S., Lawson, M. J., Hoang, S. A., Mackey, A. J., Manka, D., Cole, B. K., et al. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.11.014 · Cited by 36
“This semi-synthetic derivative of chenodeoxycholic acid (CDA) is a farnesoid X receptor (FXR) agonist and nearly 100-fold more potent than CDA (Pellicciari et al., 2002).”
BackgroundChemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists
Marino, S. D., Festa, C., Sepe, V., & Zampella, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_237 · Cited by 38
Merk, D., Lamers, C., Weber, J., Flesch, D., Gabler, M., Proschak, E., & Schubert‐Zsilavecz, M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.013 · Cited by 36
Orphan Nuclear Receptors and the Regulation of Nutrient Metabolism: Understanding Obesity
Pearen, M. A., & Muscat, G. E. O. (2012) · Physiology · doi:10.1152/physiol.00007.2012 · Cited by 37
“emia (91); 2) LXR agonists that have entered”
BackgroundFXR Promotes Endothelial Cell Motility Through Coordinated Regulation of FAK and MMP-9
Das, A., Yaqoob, U., Mehta, D., & Shah, V. H. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.182725 · Cited by 40
“The novel observations we have generated are that FXR agonists: (1) induce cell motility and tube formation capacity of ECs in a FXR-MMP-9–dependent manner; (2) activate peripheral FA plaque formation through a FXR-MMP-9–dependent pathway; (3) phosphorylate FAK on Y397, but not on Y576/577, or Y925, with downstream ac…”
BackgroundPrimary biliary cholangitis: Personalizing second-line therapies
Levy, C., & Bowlus, C. L. (2024) · Hepatology · doi:10.1097/hep.0000000000001166 · Cited by 44
Zhang, Y., LaCerte, C., Kansra, S., Jackson, J. P., Brouwer, K. R., & Edwards, J. E. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.368 · Cited by 35
Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
Pοlyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154144 · Cited by 35
MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases
Sonne, D. P. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1410 · Cited by 39
Reig, A., Álvarez-Navascués, C., Vergara, M., Gómez-Domínguez, E., Gallego-Moya, A., Pérez-Medrano, I. M., Fábrega, E., Hernández-Guerra, M., Berenguer, M., Estevez, P., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001343 · Cited by 35
Meyer, U., Costantino, G., Macchiarulo, A., & Pellicciari, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0505056 · Cited by 34
Self-citationAnthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)
Merk, D., Gabler, M., Gomez, R. C., Flesch, D., Hanke, T., Kaiser, A., Lamers, C., Werz, O., Schneider, G., & Schubert‐Zsilavecz, M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.053 · Cited by 37
Cholestatic hepatocellular injury: what do we know and how should we proceed
Guicciardi, M. E., & Gores, G. J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.014 · Cited by 37
“[2] Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al.”
BackgroundKinzel, O., Steeneck, C., Schlüter, T., Schulz, A., Gege, C., Hahn, U., Hambruch, E., Hornberger, M., Spalwisz, A., Frick, K., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.070 · Cited by 35
Bacterial metabolites directly modulate farnesoid X receptor activity
Zhang, X., Osaka, T., & Tsuneda, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0045-y · Cited by 34
“The FXR potent agonist 6α-ethyl-chenodeoxycholic acid (6ECDCA) protected mice from lithocholic acidinduced cholestasis [17].”
BackgroundDesign and structural optimization of dual FXR/PPARδ activators
Schierle, S., Neumann, S., Heitel, P., Willems, S., Kaiser, A., Pollinger, J., & Merk, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00618 · Cited by 34
Kumari, A., Mittal, L., Srivastava, M., Pathak, D. P., & Asthana, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.658312 · Cited by 38
“Upon superimposition of the binding pocket of Systems C and D, there were significant conformational changes were observed in residues M262, M287, M325, F326, R328, S329, F333, Y358, Y366, M447, and W451 in System D that are responsible to accommodate ‘OCA’ in the binding pocket of FXR (Supplementary Figure S7D).”
InfluentialBile Acid Synthesis Disorders in Arabs: A 10‐year Screening Study
Al‐Hussaini, A. A., Setchell, K. D. R., Alsaleem, B., Heubi, J. E., Lone, K., Spraul, A., & Jacquemin, E. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001734 · Cited by 36
Ng, C. H., Tang, A. S. P., Xiao, J., Wong, Z. Y., Yong, J. N., Fu, C. E., Zeng, R. W., Tan, C., Wong, G. H. Z., Teng, M. L. P., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000005 · Cited by 38
“[43] OCA acts as an FXR agonist which regulates the de novo synthesis of primary bile acids.”
BackgroundInfluentialPrimary biliary cirrhosis in adults
Momah, N., & Lindor, K. D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.888950 · Cited by 35
“FXR collaborates with another nuclear receptor, retinoid X receptor, to induce the synthesis of a suppressor protein, the short heterodimeric partner (SHP).”
BackgroundInfluentialTherapy of Primary Sclerosing Cholangitis - Today and Tomorrow
Halilbasic, E., Fuchs, C. D., Hofer, H., Paumgartner, G., & Trauner, M. (2015) · Digestive Diseases · doi:10.1159/000440827 · Cited by 36
Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets
Moraes, L. A., Unsworth, A. J., Vaiyapuri, S., Ali, M. S., Sasikumar, P., Sage, T., Flora, G. D., Bye, A. P., Kriek, N., Dorchies, E., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308093 · Cited by 36
Sun, G., Jackson, C. V., Zimmerman, K. M., Zhang, L., Finnearty, C., Sandusky, G. E., Zhang, G., Peterson, R. G., & Wang, Y. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0958-4 · Cited by 41
“Obeticholic acid (OCA) is a semi-synthetic bile acid that acts on the nuclear farnesoid X receptor (FXR) which is expressed predominantly in the liver, kidney and intestine to regulate bile acid homeostasis, hepatic lipid metabolism and immune function [46, 47].”
BackgroundBiagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
Self-citationKida, T., Murata, T., Hori, M., & Ozaki, H. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00679.2008 · Cited by 33
Emerging medical therapies for severe alcoholic hepatitis
Tornai, D., & Szabó, G. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0145 · Cited by 36
“Obeticholic acid (OCA) is a selective FXR agonist that is 100-fold more potent than the endogenous ligands of the receptor.(39) By regulating bile acid synthesis and transport, FXR activation decreases cholestasis and toxic bile acid accumulation.”
BackgroundTargeting bile acid signaling for the treatment of liver diseases: From bench to bed
Duan, S., Li, X., Fan, G., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113154 · Cited by 33
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Urbani, G., Morretta, E., Monti, M. C., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159218 · Cited by 36
Self-citationRole of bile acids in overweight and obese children and adolescents
Giannini, C., Mastromauro, C., Scapaticci, S., Gentile, C., & Chiarelli, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1011994 · Cited by 32
“group substituted at the 6 position of CDCA, which is the most potent natural ligand activator of FXR (129).”
BackgroundPleiotropic functions of bile acids mediated by the farnesoid X receptor.
Stanimirov, B., Stankov, K., & Mikov, M. (2012) · PubMed · Cited by 40
Beuers, U. H., Kullak-Ublick, G. A., Pusl, T., Rauws, E. A., & Rust, C. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8085-y · Cited by 33
“6-ECDCA prevented bile flow impairment induced by both LCA and E217α and protected hepatocytes against acute necrosis caused by LCA [55, 56].”
InfluentialDeng, G., Li, W., Shen, J., Jiang, H., Chen, K., & Liu, H. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.027 · Cited by 30
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease
Yu, D. D., Andrali, S. S., Li, H., Lin, M., Huang, W., & FORMAN, B. M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.039 · Cited by 31
A novel intestinal-restricted FXR agonist
Wang, H., Hao, H., Zhou, J., Guo, Y., Wang, G., Hao, H., & Xu, X. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.003 · Cited by 32
Fiorucci, S., Biagioli, M., Baldoni, M., Ricci, P., Sepe, V., Zampella, A., & Distrutti, E. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916465 · Cited by 30
Self-citationNatalini, B., Sardella, R., Camaioni, E., Gioiello, A., & Pellicciari, R. (2007) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-007-1360-6 · Cited by 31
Self-citationCostantino, G., Entrena-Guadix, A., Macchiarulo, A., Gioiello, A., & Pellicciari, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049182o · Cited by 33
Self-citationABCB4: Insights from pathobiology into therapy
Falguières, T., Aït‐Slimane, T., Housset, C., & Maurice, M. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.03.001 · Cited by 38
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Current research on the treatment of primary sclerosing cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01018 · Cited by 35
“Obeticholic acid (OCA, INT-747), a 6-ethyl derivative of the natural human bile acid chenodeoxycholic acid (CDCA), is a first-in-class selective FXR agonist with ~ 100-fold greater FXR agonistic activity than CDCA (39-41).”
BackgroundFXR Agonists: From Bench to Bedside, a Guide for Clinicians
Alawad, A. S., & Levy, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4334-8 · Cited by 31
“In particular, in the only study Table 1 Preclinical studies evaluating the use of FXR agonists Study target Finding Author/FXR agonist/ Year Insulin resistance In rabbits fed with a high-fat diet, OCA improved glucose tolerance Vignozzi (OCA), 2011 In rats with loss of function of leptin receptors, OCA reversed insul…”
BackgroundInfluentialSecond-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics
Helmstädter, M., Kaiser, A., Brunst, S., Schmidt, J., Ronchetti, R., Weizel, L., Proschak, E., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00831 · Cited by 30
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists
Tognolini, M., Incerti, M., Pala, D., Russo, S., Castelli, R., Hassan‐Mohamed, I., Giorgio, C., & Lodola, A. (2013) · ChemMedChem · doi:10.1002/cmdc.201300305 · Cited by 31
3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators
Honorio, K. M., Garratt, R. C., Polikarpov, I., & Andricopulo, A. D. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2006.09.003 · Cited by 30
Stahl, S. H., Davies, M. R., Cook, D. I., & Graham, M. J. (2008) · Xenobiotica · doi:10.1080/00498250802105593 · Cited by 35
“Indeed, incubation of cultured hepatoma cells with CDCA results in lower HNF1 mRNA and protein levels (Jung and Kullak-Ublick 2003a).”
BackgroundInfluentialFarnesoid X receptor modulators (2011 – 2014): a patent review
Sepe, V., Distrutti, E., Fiorucci, S., & Zampella, A. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1045413 · Cited by 33
“In detail, the introduction of an ethyl at C-6 on the CDCA ring B afforded to the disclosure of the potent FXR agonist, 6a-ethyl-chenodeoxycholic acid (6-ECDCA)/OCA (Figure 3)/ INT-747 reported in both peer-reviewed literature [26] and in two patent applications of 2002 and 2005 [27].”
BackgroundSelf-citationLeva, F. S. D., Festa, C., Renga, B., Sepe, V., Novellino, E., Fiorucci, S., Zampella, A., & Limongelli, V. (2015) · Scientific Reports · doi:10.1038/srep16605 · Cited by 32
Self-citationThe Farnesoid X Receptor A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Rader, D. J., Hama, S. Y., Hough, G. P., Yu, N., & Ansell, B. J. (2005) · Cited by 29
Bijsmans, I. T. G. W., Guercini, C., Pittol, J. M. R., Omta, W. A., Milona, A., Lelieveld, D., Egan, D. A., Pellicciari, R., Gioiello, A., & van Mil, S. W. C. (2015) · Scientific Reports · doi:10.1038/srep14086 · Cited by 35
Self-citationFesta, C., Marino, S. D., Carino, A., Sepe, V., Marchianò, S., Cipriani, S., Leva, F. S. D., Limongelli, V., Monti, M. C., Capolupo, A., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00162 · Cited by 28
“In detail, the introduction of an ethyl group at C-6 on the CDCA afforded to the disclosure of 6-ECDCA/OCA (Figure 1B)/INT-747 endowed with high potency toward FXR (Pellicciari et al., 2002).”
BackgroundSelf-citationNonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Jeong, S. W. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0115 · Cited by 30
“Finally, OCA exerts anticholestatic and hepatoprotective effects by regulating the metabolism of cholesterol and bile acids [33].”
BackgroundPathogenesis of NASH and Promising Natural Products
Leng, Y., Zhang, M., Luo, J., & Zhang, H. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60002-x · Cited by 34
Liu, Z., Law, W.-K., Wang, D., Nie, X., Sheng, D., Song, G., Guo, K., Wei, P., Ouyang, P., Wong, C., et al. (2014) · RSC Advances · doi:10.1039/c3ra46715e · Cited by 30
Yang, L., Broderick, D. J., Jiang, Y., Hsu, V. L., & Maier, C. S. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.06.007 · Cited by 29
Xiao, H., Li, P., Li, X., He, H., Wang, J., Guo, F., Zhang, J., Wei, L., Zhang, H., Shi, Y., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00318 · Cited by 28
Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
van Hooff, M. C., Werner, E., & van der Meer, A. J. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.030 · Cited by 32
A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid
He, X., Wang, L., Gu, X.-Z., Xiao, J.-X., & Qiu, W. (2018) · Steroids · doi:10.1016/j.steroids.2018.10.009 · Cited by 27
Prediction of Farnesoid X Receptor Disruptors with Machine Learning Methods
Chen, Y., Yang, H., Wu, Z., Liu, G., Tang, Y., & Li, W. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00162 · Cited by 28
Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer
Yin, Y., Wang, M., Gu, W., & Chen, L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114430 · Cited by 27
Primary biliary cirrhosis and bile acids
Corpechot, C. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70016-5 · Cited by 28
Macchiarulo, A., Gioiello, A., Thomas, C., Massarotti, A., Nuti, R., Rosatelli, E., Sabbatini, P., Schoonjans, K., Auwerx, J., & Pellicciari, R. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800196h · Cited by 26
Self-citationChang, J., Go, S., Verhoeven, A. J., Beuers, U. H., & Elferink, R. P. J. O. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.022 · Cited by 32
Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors
Marschall, H., Wagner, M., Zollner, G., & Trauner, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060133c · Cited by 30
Bile acids and their receptors in hepatic immunity
Fiorucci, S., Marchianò, S., Distrutti, E., & Biagioli, M. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.005 · Cited by 31
Self-citationNatalini, B., Sardella, R., Camaioni, E., Macchiarulo, A., Gioiello, A., Carbone, G., & Pellicciari, R. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.10.035 · Cited by 26
Self-citationFarnesoid X receptor modulators: a patent review
Crawley, M. L. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.496777 · Cited by 26
“This is best exemplified by the disclosure of 6a-ethylCDCA (6-ECDCA, also known as INT-747 4) as a potent FXR agonist, both in peer-reviewed literature [15] and the respective patent applications (Figure 2) [16,17].”
BackgroundMcIlvride, S., Nikolova, V., Fan, H. M., McDonald, J. A. K., Wahlstrom, A. M., Bellafante, E., Jansen, E. H. J. M., Adorini, L., Shapiro, D., Jones, P. M., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00407.2018 · Cited by 28
“Obeticholic acid (OCA) is a bile acid analog with markedly higher affinity for FXR than the natural ligand, chenodeoxycholic acid (47).”
BackgroundFarnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis
Ding, C., Wang, Z., Dou, X., Yang, Q., Ning, Y., Kao, S., Sang, X., Hao, M., Wang, K., Peng, M., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0830 · Cited by 43
Zhao, J., Li, B., Zhang, K., & Zhu, Z. (2024) · Medicine · doi:10.1097/md.0000000000037271 · Cited by 29
“[20,21] OCA binds to and activates FXR, leading to increases in fibroblast growth factor-19 (FGF19) secretions by the ileum.”
BackgroundCurrent Landscape and Evolving Therapies for Primary Biliary Cholangitis
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13181580 · Cited by 31
“Therefore, a decrease in butyrate-producing bacteria could result in impaired MDSC function and a suboptimal response to UDCA treatment, suggesting that microbiota-targeted therapies could have therapeutic potential in PBC patients.”
BackgroundSelf-citationPrimary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
Abenavoli, L., Procopio, A. C., Fagoonee, S., Pellicano, R., Carbone, M., Luzza, F., & Invernizzi, P. (2020) · Diseases · doi:10.3390/diseases8020020 · Cited by 26
“Specifically, it has been observed that the introduction of an alkyl group on the C-6 of ring B significantly improved the activity [41].”
BackgroundFarnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets
Maliha, S., & Guo, G. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.02.002 · Cited by 24
Cai, K., & Sewer, M. B. (2013) · Biochemical Journal · doi:10.1042/bj20130609 · Cited by 29
Novel stereoselective synthesis and chromatographic evaluation of E-guggulsterone
Gioiello, A., Sardella, R., Rosatelli, E., Sadeghpour, B. M., Natalini, B., & Pellicciari, R. (2011) · Steroids · doi:10.1016/j.steroids.2011.11.012 · Cited by 25
Self-citationBile Acid Analog Intercepts Liver Fibrosis
Filho, C. D. D. M., Downes, M., & Evans, R. M. (2016) · Cell · doi:10.1016/j.cell.2016.08.001 · Cited by 25
Edwards, J. E., Eliot, L., Parkinson, A., Karan, S., & MacConell, L. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0601-0 · Cited by 27
“FXR-responsive elements are also located in the promoter regions of both organic solute transporter a/b (OST a/b) genes [10].”
BackgroundInfluentialPennisi, G., Celsa, C., Spatola, F., Dallio, M., Federico, A., & Petta, S. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16224334 · Cited by 33
“It is approximately 100-fold potent than CDCA for FXR activation [34].”
BackgroundLi, M. H., Chen, W., Wang, L., Sun, J. L., Zhou, L., Shi, Y., Wang, C. H., Zhong, B. H., Shi, W. G., & Guo, Z. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255216 · Cited by 24
“Transactivation assays of RLA8 and ZBH toward PPARs, GPR40, GPBAR1 (G protein bile acid receptor 1), and FXR were performed according to previously described protocols (Xu and Xie, 2009; Chen et al., 2014; Gao et al., 2018).”
BackgroundInfluential
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.